The invention provides compounds of the formula (I) having protein kinase B inhibiting activity: wherein A is a saturated hydrocarbon linker group containing from 1 to 7 carbon atoms, the linker group having a maximum chain length of 5 atoms extending between R1 and NR2R3 and a maximum chain length of 4 atoms extending between E and NR2R3, wherein one of the carbon atoms in the linker group may optionally be replaced by an oxygen or nitrogen atom； and wherein the carbon atoms of the linker group A may optionally bear one or more substituents selected from oxo, fluorine and hydroxy, provided that the hydroxy group when present is not located at a carbon atom a with respect to the NR2R3 group and provided that the oxo group when present is located at a carbon atom a with respect to the NR2R3 group； E is a monocyclic or bicyclic carbocyclic or heterocyclic group； R1 is an aryl or heteroaryl group； and R2, R3, R4 and R5 are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds, methods for preparing the compounds and their use as anticancer agents.本發明係提供具有蛋白質激酶B抑制活性之式(I)化合物：其中A為含有1至7個碳原子之飽和烴連結基，此連結基具有一個最大鏈長為5個原子，延伸於R1與NR2R3之間，與一個最大鏈長為4個原子，延伸於E與NR2R3之間，其中連結基中碳原子之一可視情況被氧或氮原子置換；且其中連結基A之碳原子可視情況帶有一或多個取代基，選自酮基、氟及羥基，其條件是羥基當存在時係不位在相對於NR2R3基團α位之碳原子處，且其條件是酮基當存在時係位在相對於NR2R3基團α位之碳原子處；E為單環狀或雙環狀碳環族或雜環族基團；R1為芳基或雜芳基；且R2,R3,R4及R5均如請求項中之定義。；亦提供含有此等化合物之醫藥組合物，製備此等化合物之方法，及其作為抗癌劑之用途。
